Latest news with #BingLi
Bloomberg
2 days ago
- Business
- Bloomberg
Countdown to Compliance: Getting Ready for the September Rewrite
The upcoming HKMA/SFC OTC Derivatives Reporting Rewrite builds on the global foundation of regulatory reporting reforms. The objective is clear: to ensure reported data is not only accurate, but also actionable and meaningful for both regulators and market participants. With fewer than 12 weeks remaining, now is the time to ensure you have the right tools and technology partnerships in place to meet this challenge—and come out ahead. Join regulatory representatives and industry experts as we explore: The current state of readiness across the industry: how various firms are approaching the rewrite and what trends are emerging Evolving regulatory expectations: what regulators aim to achieve through the changes Tools and solutions available in the market to support compliance and efficiency Lessons learned: tips and best practices drawn from previous global regulatory rewrites This in-person seminar will conclude with a networking session and refreshments. Speakers Bing Li Head of Asia Pacific Bloomberg L.P. Bing Li oversees Bloomberg's financial information and enterprise business across the Asia Pacific region. Based in Hong Kong, he is responsible for the firm's business and product strategy, including the Bloomberg Terminal, the world's most trusted source of financial data, news and analytics for global investors, leading financial institutions and corporations. Mr. Li has decades of experience in global bond markets and is a frequent commentator on investing in Greater China's financial markets. Mr. Li was previously Head of Greater China at Bloomberg (a role he still retains), leading the team to provide customers with best-in-class data, analytics, trading tools and market connectivity. He has also driven a number of strategic partnerships with key regulators and leading financial institutions to advance the region's financial market development. Under Mr. Li's leadership, the Greater China region has been the fastest growing market for the company. Prior to joining Bloomberg, Mr. Li was head of Fixed Income at Bank of China (Hong Kong), responsible for sales, trading and research. Mr. Li joined the bank from Tandem Global Partners, a New York based Fixed Income asset manager, where he was a partner and portfolio manager covering the Asia Pacific region. Before Tandem, Mr. Li served as Vice President at Deutsche Bank in Hong Kong and was a core team member of the Equity Derivatives department. Mr. Li worked for HSBC and then JP Morgan in the early years of his career, where he traded bonds and fixed income derivatives. Mr. Li earned his B.A. from Rutgers University. Ronald Lau Manager Hong Kong Trade Repository (HKTR) Ronald Lau is a Manager at the HKMA's Financial Market Infrastructures – Trade Repository. He is an experienced central banking professional with over 16 years at the HKMA, including more than 13 years with the Hong Kong Trade Repository. He has been instrumental in overseeing the development and implementation of the Hong Kong Trade Repository (HKTR) system. With over a decade of experience in financial market infrastructure, Ronald has played a pivotal role in ensuring the system's stability and reliability, whilst also driving alignment with evolving international standards. His work has been crucial in assisting the industry in fulfilling requirements under the OTC Regulatory Regime by leveraging the HKTR's Trade Reporting Service. Ronald holds a Masters degree in Information System Management from the City University of Hong Kong and earned his from the University of British Columbia. Emma Kalliomaki Managing Director, Association of National Numbering Agencies (ANNA) Managing Director of the Derivatives Service Bureau (DSB) Emma Kalliomaki is a Managing Director of ANNA as well as the Managing Director of the Derivatives Service Bureau (DSB), an organisation originally founded by ANNA, working in collaboration with the industry as the fully automated global generator of ISINs, CFIs, FISNs and UPIs for Over the Counter (OTC) derivatives. Emma leads the work of ANNA and the DSB boards in delivering on their mandates to develop and implement international standards that foster market transparency, stability and efficiency, and help organisations meet regulatory requirements. Emma is a sought-after industry speaker and a leading industry commentator, spearheading collaborative work programmes with regulators, market participants and infrastructure service providers. Emma has 20 years of experience in financial data, standards and regulation. Prior to ANNA and the DSB, Emma spent more than a decade working at the London Stock Exchange Group, where she was head of the London Stock Exchange's reference data operations which included the launch of their Legal Entity Identifier solution and leading ISO standardisation related activities. Emma also represents ANNA as a liaison organisation to ISO TC68 (Financial Services) and SC8 (Reference data for financial services) and is an appointed member of the UK Transforming Data Collection Industry Standards Data Committee, which is a joint initiative of the Bank of England and FCA. Xiangjing Ng Senior Director of Public Policy, Asia Pacific International Swaps and Derivatives Association (ISDA) Ng Xiangjing is the Senior Director of Public Policy for Asia Pacific at the International Swaps and Derivatives Association (ISDA), where he leads the organization's public policy efforts in the region. He is an experienced public policy professional with over 18 years of experience in financial markets development and regulatory reforms. Prior to joining ISDA, Xiangjing spent over 15 years at the Monetary Authority of Singapore, where he held various roles. He spearheaded a team to drive the development of Singapore's derivatives and equities market, such as establishing Singapore as a preeminent global FX electronic trading hub, and facilitating launch of new derivative products such as FX futures. Xiangjing also played a key role in shaping regulatory policies in the financial industry. He was involved in the implementation of G20 OTC derivatives regulatory reforms in Singapore, including trade reporting, clearing, and trading, and was instrumental in the set-up of the trade repository in Singapore. Josh (Lemuel) Reyes Associate Director HSBC's Markets and Securities Services Lemuel Reyes (for most people he is known by his nickname, Josh) is an Associate Director at HSBC's Markets and Securities Services – Market Operations, Regulatory Response and Oversight. He's been in the financial industry for 20+ years where 10+ years of that is on regulatory reporting particularly on ASP over-the-counter derivatives. He has been involved in the implementation of various ASP rewrites i.e. Japan, Australia and Singapore and now working on the Hong Kong rewrite. Josh was also involved in the implementation of the HKMA Risk Mitigation Standards and HKMA Granular Data Reporting. Josh is from the Philippines and has moved to Hong Kong in 2011. Satish Vyamajala Head of G20 Regulatory Reporting Product Bloomberg Satish Vyamajala is the Head of G20 regulatory reporting product at Bloomberg. He has more than 18 years of experience in financial services industry and has spent over 10 years implementing regulatory solutions across both buy side and sell side firms. His domain expertise spans across all G20 regs – CFTC, EMIR, MAS, ASIC, HKMA etc. Satish has a Masters degree in Finance and IT systems from T A Pai Management Institute, India and Bachelors in Mechanical Engineering from J N T University, Hyderabad, India. VICKY CHENG Head of Government and Regulatory Affairs, APAC BLOOMBERG L.P. Vicky Cheng is Head of Government and Regulatory Affairs Asia Pacific, overseeing government relations and regulatory developments impacting Bloomberg and its clients in the region. Before joining Bloomberg, Vicky worked in both the public and private sectors. Her focus has been policy and regulatory development, advising senior management on related requirements and implementations. Vicky drove advocacy and public affairs programmes for various organizations including global corporates and financial institutions. During her time with an international law firm, Vicky led business development and thought leadership strategies for the Financial Services Regulatory and Dispute Resolution practices. She began her career with a Government providing policy analysis and communications.
Korea Herald
23-05-2025
- Business
- Korea Herald
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /PRNewswire/ -- Intalight ™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT ™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. "Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients." DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT ™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. "Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know." Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. "This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval." As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT ™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook.
Cision Canada
15-05-2025
- Business
- Cision Canada
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging Français
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /CNW/ -- Intalight ™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT ™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. "Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients." DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT ™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. "Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know." Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. "This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval." As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT ™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook.
Yahoo
15-05-2025
- Business
- Yahoo
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /CNW/ -- Intalight™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. "Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT," said Intalight chairman and Founder, Shawn Peng. "This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients." DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. "Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth," said Intalight CEO and Co-Founder, Bing Li. "DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know." Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. "This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US," remarked Intalight Chief Commercial Officer, Joe Garibaldi. "We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval." As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook. View original content to download multimedia: SOURCE Intalight Inc. View original content to download multimedia:
Associated Press
15-05-2025
- Business
- Associated Press
Intalight™ Receives CE Mark for Its Progressive DREAM OCT™ Swept Source Imaging
SAN JOSE, Calif. and SHANGHAI, May 15, 2025 /CNW/ -- Intalight™, a company that develops advanced ophthalmic technologies and a leader in Optical Coherence Tomography (OCT) today announced it has received CE mark for its DREAM OCT™ platform. The CE mark serves as approval by the European Union (EU) to commercialize DREAM OCT, the newest version of OCT. DREAM stands for: Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities. The imaging platform provides the highest quality OCT images currently on the market. 'Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT,' said Intalight chairman and Founder, Shawn Peng. 'This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients.' DREAM OCT is able to cover an ultrawide field single scan which delivers a 130° OCTA image. DREAM OCT™ swept-source 12 mm super-depth scanning allows superior imaging of the choroid and retina, and a large portion of the vitreous space. The super-depth anterior scanning capabilities achieves 16.2 mm (in air), allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be scanned in only one scan. The longer wavelength allows for superior penetration through opacities in either lens or vitreous. 'Over the past few years, we've heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth,' said Intalight CEO and Co-Founder, Bing Li. 'DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP's know.' Using ultra-wide swept-source technology, DREAM OCT was developed to address the needs of retina specialists, comprehensive ophthalmologists and their patients with highly-detailed imaging capabilities for improved care and results. Currently, more than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. 'This is such exciting news for Intalight that there's no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US,' remarked Intalight Chief Commercial Officer, Joe Garibaldi. 'We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval.' As the clinically validated leader of ultra-wide field OCTA, Intalight is currently collaborating with the top retina academic institutions and retina private practices in the United States, Europe, and Asia. About Intalight Intalight Inc. was founded by a group of scientists and industry veterans of Silicon Valley with a core mission to develop the most advanced ophthalmic technologies. There are now three sites in Silicon Valley, Shanghai, and Luoyang. Intalight's Swept-Source Optical Coherence Tomography (OCT) device combines Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate lesion detection and Multimodal imaging capabilities, and is abbreviated as DREAM OCT™. The powerful imaging device has become an indispensable tool for many ophthalmologists in not only their daily clinical use but also their exploration of the research frontiers. To learn more about Intalight and DREAM OCT, please visit our website at and follow us on LinkedIn and Facebook. View original content to download multimedia: SOURCE Intalight Inc.
